MedTrace Logo

Contrast Enhanced Spectral Mammography (CESM) Study

NCT02479100 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-02-28

No results posted yet for this study

Summary

The aim of this study is to determine if the addition of Contrast Enhanced Spectral Mammography (CESM) to standard diagnostic imaging, results in a decision regarding patient management - discharge, follow-up, surgery or treatment - being made sooner than it would if the patient had followed the standard course of investigations and review.

Conditions

Interventions

DIAGNOSTIC_TEST

Contrast Enhanced Spectral Mammogram

Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care

Sponsors & Collaborators

  • University of Cambridge

    collaborator OTHER

  • GE Healthcare

    collaborator INDUSTRY

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Fiona J Gilbert, FRCR · University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-22
Primary Completion
2019-03-31
Completion
2022-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479100 on ClinicalTrials.gov